{"entity":{"type":"insider","cik":"0001550192","url":"/insider/0001550192","json_url":"/insider/0001550192.json","name":"IDG-Accel China Growth Fund III Associates L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":4,"n_filings":2,"first":"2016-01-27","last":"2018-03-23","span_basis":"filed_date"},"name_variants":[{"name":"IDG-Accel China Growth Fund III Associates L.P.","source":"filing","n_filings":2,"first_seen":"2016-01-27","last_seen":"2018-03-23"}],"transactions":[{"id":6648165,"accession":"0000950103-18-003689","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950103-18-003689","line_url":"/filing/0000950103-18-003689","is_derivative":false,"issuer_cik":"0000895051","issuer_name":"CASI Pharmaceuticals, Inc.","issuer_ticker":"CASI","issuer_name_source":null,"issuer_url":"/issuer/0000895051","owner_cik":null,"owner_name":"Ho Chi Sing; Zhou Quan; IDG-Accel China Growth Fund III L.P.; IDG-Accel China Growth Fund GP III Associates Ltd.; IDG-Accel China Growth Fund III Associates L.P.; IDG-Accel China III Investors L.P.","owner_display_name":"Ho Chi Sing","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3086418.0,"shares_display":"3,086,418","price_per_share":3.19,"price_display":"3.19","price_state":"stated","total_value":9845673.42,"total_display":"9,845,673.42","total_whole":"9,845,673","shares_owned_after":9126375.0,"shares_owned_after_display":"9,126,375","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-21","filed_date":"2018-03-23","scope":"insider","n_lines":2},{"id":2269735,"accession":"0000950103-16-010539","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950103-16-010539","line_url":"/filing/0000950103-16-010539","is_derivative":false,"issuer_cik":"0000895051","issuer_name":"CASI Pharmaceuticals, Inc.","issuer_ticker":"CASI","issuer_name_source":null,"issuer_url":"/issuer/0000895051","owner_cik":null,"owner_name":"IDG-Accel China Growth Fund III L.P.; IDG-Accel China III Investors L.P.; Ho Chi Sing; IDG-Accel China Growth Fund III Associates L.P.; Zhou Quan; IDG-Accel China Growth Fund GP III Associates Ltd.","owner_display_name":"IDG-Accel China Growth Fund III L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1041666.0,"shares_display":"1,041,666","price_per_share":2.4,"price_display":"2.40","price_state":"stated","total_value":2499998.4,"total_display":"2,499,998.40","total_whole":"2,499,998","shares_owned_after":5091438.0,"shares_owned_after_display":"5,091,438","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-07","filed_date":"2016-01-27","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000895051","name":"CASI Pharmaceuticals, Inc.","url":"/issuer/0000895051","role":"Ten percent owner","n_filings":2,"first_seen":"2016-01-27","last_seen":"2018-03-23"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001550192","retrieved_at":"2026-08-23T16:27:48+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}